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Outline 
 
• the interplay between values and evidence in screening 
policy 
 
• methods of an ongoing systematic review 
 
• examples of disinvestment decisions 
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Population screening 
• Screening is: 
– “Testing people who either do not or have not recognized the 
signs or symptoms of the condition being tested for. In other 
words, they believe themselves to be well in relation to the 
disease that the screening relates to” 
– “Where the stated or implied purpose is to reduce risk for that 
individual of future ill health in relation to the condition being 
tested for, or to give information about risk that is deemed 
valuable for that individual even though risk cannot be altered” 
– “It encompasses the whole system or programme of events 
necessary to achieve risk reduction. Screening is a programme 
not a test.” (Raffle & Gray, 2007; p37) 
• Examples include: Newborn bloodspot screening, 
prostate cancer screening, cervical cancer screening, 
breast cancer screening 
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Taking prostate screening as an 
example 
Professional Organization Year of latest 
Recommendation 
American Cancer Society 2012 
American College of Physicians 2013 
Canadian Task force on Preventive Health Care 2014 
European Society for Medical Oncology 2013 
Prostate Cancer Canada 2013 
United States Preventive Services Task Force (USPSTF) 2012 
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When the evidence 
recommendations disagree 
• Canadian Agency for Drugs Technology 
and Health (CADTH) review (Prostate 
Cancer Screening, 2013):  
 
“Almost all the included guidelines 
reported that their recommendations 
were based on a balance between 
the benefits and harms of screening; 
however, the specific outcomes 
reviewed in each guideline and the 
weights given for each outcome 
varied from one guideline to 
another.” 
 
• Clinical Practice Guidelines (CPG) issued 
from the Royal Australasian College of 
General Practitioners (7th edn. 2009) 
stated that men aged 55–69 years 
should not be offered PSA testing 
routinely whereas CPG from the 
Urological Society of Australia and New 
Zealand stated they should 
(2009)(Scott & Guyatt, 2013). 
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Evidence review process: Variation 
6 
Seedat F, Cooper J, Cameron L, et al. International comparisons of screening policy-making: A 
systematic review, 2014. URL: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/444227/FINAL_RE
PORT_International_Screening.pdf 
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Stopping screening: controversy 
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Screening decisions, evidence-based 
medicine, and values 
•CTFPHC recommendations on prostate screening (Oct 2014). 
–[the CTFPHC] “rated the quality of evidence and strength of 
recommendations using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system. However, it paid 
insufficient attention to patient values, patient preferences and 
costs.” (Krahn, 2014) 
 
•Are agreements/disagreements about evidence, or values? (Atkins et al., 
2005) 
 
–“Disease prevention can only be understood in a political as well as a 
medical context. Medical knowledge provides a technological base 
for the analysis of policy options. However, it is the political 
process, reflecting the power and values of the several 
constituencies in society, that will determine which choices are 
made.”(Eisenberg, 1984) 
 
8 
Krahn M. Prostate cancer screening: going beyond the clinical evidence. CMAJ 2014. 
Eisenberg L. Prevention: rhetoric and reality. J R Soc Med 1984; 77: 268-280. 
Atkins D, Siegel J, Slutsky J. Making policy when the evidence is in dispute. Health Aff 2005; 24: 102-113. 
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Research objective(s) 
• The goal of this review is to conduct a critical interpretive synthesis (CIS) to 
better understand the stated rationales for disinvestment from established 
population screening programs. In doing so we will: 
 
– Identify examples of population screening programs recommended for 
disinvestment and describe their characteristics 
  
– Generate a matrix of factors associated with recommendations to 
disinvest from existing screening programs and compare these with 
established criteria for the implementation of population screening 
 
– Elicit the values which underpin disinvestment recommendations.   
 
– Generate a categorization framework of disinvestment decision-
types 
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Research objective(s) 
• The goal of this review is to conduct a critical interpretive synthesis (CIS) to 
better understand the stated rationales for disinvestment from established 
population screening programs. In doing so we will: 
 
– Identify examples of population screening programs recommended for 
disinvestment and describe their characteristics 
  
– Generate a matrix of factors associated with recommendations to 
disinvest from existing screening programs and compare these with 
established criteria for the implementation of population screening 
 
– Elicit the values which underpin disinvestment recommendations.  
(i.e. theory/concept development) 
 
– Generate a categorization framework of disinvestment decision-
types 
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• Issues 
– Diffuse literature 
– Heterogenous literature (large proportion 
grey literature) 
– Qualitative and quantitative studies 
– Not aggregative; interpretive 
• Strategy 
– A critical interpretive synthesis (CIS) 
approach 
11 
Critical interpretative synthesis  
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Critical interpretive Synthesis (CIS) 
Entwistle V, Firnigl D, Ryan M, Francis J, Kinghorn P. Which experiences of health care delivery matter to 
service users and why? A critical interpretive synthesis and conceptual map. Journal of Health Services 
Research and Policy 2012, 17:70 
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Comparison of Systematic review & 
CIS 
Systematic Review/Meta 
analyses 
Critical Interpretive Synthesis 
(CIS) 
Test theories Generate theories 
Aggregative synthesis Interpretive synthesis 
Summarizing data Theory grounded in included studies 
Explicit searching strategies- clear account of 
search for reproducibility reasons 
‘organic’ search process- electronic databases, 
websites, reference chaining, use of experts 
within review team 
Identification of all relevant material Potentially relevant papers to provide a sampling 
frame 
Specific boundaries Boundaries diffused and ill-defined 
Summary of ALL available data Development of concepts and theory, not an 
exhaustive summary of all data- purposive 
sampling and theoretical sampling 
Study design hierarchy No hierarchy of study designs 
Data extraction forms to identify 
characteristics of studies in a systematic way 
Informal methods and data forms 
Analyses Identify recurring themes and developing a 
critique 
Answerable question Meaningful question/ exploratory 
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Eligibility Criteria 
 
– Qualitative or quantitative studies that report on revisions 
and or amendments to an established population screening 
program- an iterative process of modifying and refining of 
review question, a reflection of the complexity, scope and 
nature of the review 
 
– Studies on population-based screening programs-
newborns/children/adults 
– Recommendation(s) to disinvest- deintensify and or deimplement 
– Recommendation can be international, national or provincial 
– No restriction on time recommendation was made 
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Iterative process 
 
 
 
 
 
 
 
 
• USPSTF-United States Preventive Services Task force on Prostate Screening 
• PSA- prostate -specific antigen, DRE- Digital Rectal Exams 
 
Year Age Modality Recommendation 
2002 Any age PSA test Insufficient evidence 
to make a 
recommendation 
2008 Less than 75 years 
 
 
75 Years or older 
PSA test 
 
 
PSA test 
Insufficient evidence 
to make a 
recommendation 
 
Not Recommended 
2012 Any Age PSA Test Not Recommended 
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16 
Total records screened after duplicates removed 
(n=8088) 
 
Studies included 
(n=11) 
Records excluded (n=6853) 
*not a population screening 
program 
*Opportunistic screening 
*no recommendation 
*Recommendation for 
treatment/surveillance 
Full-text articles assessed for eligibility 
(n=1235) 
 
Records excluded 
(n=1224) 
Records identified through electronic 
search strategy  
(n=9570) 
 
Documents from reference lists and 
grey literature 
(n=In progress) 
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Results: A range of screening 
programs 
• Toxoplasmosis (Denmark): “no evidence of lasting benefit” (Prosser et 
al, 2012) 
• Neuroblastoma: ended because of “no benefit from population 
screening, in terms of mortality rates.” (Botkin, 2005) 
• Cervical Cancer 
• Prostate cancer 
• Mammography 
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Results: An emphasis on evidence (as 
opposed to recommendations) 
• The language of (for) disinvestment in the literature is 
vague 
• Emphasis on evidence, abstract from a programmatic 
decision about what to do with the data  
– ‘…there is a large body of evidence supporting 2-yearly screening 
of women aged 50-69 years’ (Evans and Whelehan, 2011) 
– ‘… no evidence to suggest that a single screen between the ages of 
47 and 50 within a programme screening at 3-year intervals will 
reduce mortality’ (Evans and Whelehan, 2011) 
– …. ‘the emphasis should be on utilizing evidence-based medicine to 
reduce overdiagnosis and overtreatment through less frequent 
screening’ (Makovey 2013) 
 
Makovey I, Stephenson AJ, Haywood S. Response to the U.S. Preventative Services Task Force decision on prostate cancer screening. Curr Urol Rep. 2013 Jun; 
14(3):168-73 
Evans A, Whelehan P. Breast screening policy: are we heading in the right direction? Clin Radiol. 2011 Oct;66(10):915-9. 
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Results: Actively seeking the absent 
• Recommendations tend to focus on micro, not macro 
issues: 
– Morbidity (lack of reduction in) 
– Mortality (as above) 
– Test quality 
• Little if any mention of cost or cost-effectiveness 
– Contrast with many jurisdictional processes where 
cost per QALY or other metric is used for 
IMPLEMENTATION 
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Implicit values revealed: rationales 
inconsistent with established criteria 
• There are concerns about the 
reliability of the current test  
• While there is evidence that long 
term steroid treatment is beneficial, 
the optimum time at which it should 
be started remains uncertain  
• There is insufficient evidence that 
identifying newborns with DMD by 
screening improves long term 
health compared to current practice  
• It is not clear from the research 
what the impact of early diagnosis is 
on parents’ subsequent reproductive 
decision making  
• (UK National Screening Committee. Policy 
Review. Screening in the UK 2011-2012, UK 
National Screening Committee: London, UK 
2012., P..13)  
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Implicit values revealed: rationales 
inconsistent with established criteria 
• There are concerns about the 
reliability of the current test  
• While there is evidence that long 
term steroid treatment is beneficial, 
the optimum time at which it should 
be started remains uncertain  
• There is insufficient evidence that 
identifying newborns with DMD by 
screening improves long term 
health compared to current practice  
• It is not clear from the research 
what the impact of early 
diagnosis is on parents’ 
subsequent reproductive 
decision making  
• (UK National Screening Committee. Policy 
Review. Screening in the UK 2011-2012, UK 
National Screening Committee: London, UK 
2012., P..13)  
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Summary 
• CIS provides an approach that is flexible given a diffuse 
and heterogenous literature 
• Can incorporate traditional systematic review processes 
(e.g. systematic search), but has a different outlook 
• Interpretative, as opposed to aggregative, analysis may 
throw into light missing elements or may emphasis 
contrasts that instigate further 
consideration/assessment 
• To date little explicit and published consideration of 
disinvestment from screening 
• A focus on health, not health systems 
• Value systems are embedded and need further 
exploration and explication 
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Thank you for your attention 
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